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We analyzed databases spanning 50 years, which 
included retrospective alveolar echinococcosis (AE) case-
fi nding studies and databases of the 3 major centers for 
treatment of AE in Switzerland. A total of 494 cases were 
recorded. Annual incidence of AE per 100,000 population 
increased from 0.12–0.15 during 1956–1992 and a mean 
of 0.10 during 1993–2000 to a mean of 0.26 during 2001–
2005. Because the clinical stage of the disease did not 
change between observation periods, this increase cannot 
be explained by improved diagnosis. Swiss hunting statistics 
suggested that the fox population increased 4-fold from 
1980 through 1995 and has persisted at these higher levels. 
Because the period between infection and development of 
clinical disease is long, the increase in the fox population 
and high Echinococcus multilocularis prevalence rates in 
foxes in rural and urban areas may have resulted in an 
emerging epidemic of AE 10–15 years later.
Human alveolar echinococcosis (AE), a hepatic disor-der that resembles liver cancer, is a highly aggressive 
and lethal zoonotic infection caused by the larval stage of 
the fox tapeworm, Echinococcus multilocularis (1). The 
parasite is widely distributed in the Northern Hemisphere; 
the disease-endemic area stretches from North America 
through Europe to central and east Asia, including northern 
parts of Japan (1–3). Parasite eggs are shed into the envi-
ronment in the feces of canid defi nitive hosts that harbor the 
adult parasite in their intestines. In addition, some of these 
eggs contaminate the fur of infected defi nitive hosts. Hu-
mans and intermediate host animals acquire the infection 
by ingesting E. multilocularis eggs in contaminated food or 
water or by having close physical contact with infected fox-
es, dogs, or host feces. In Europe, E. multilocularis exists 
predominantly in a cycle of wild animals that includes red 
foxes (Vulpes vulpes) as main defi nitive hosts and several 
vole species as intermediate hosts. In the United States and 
Canada, the coyote (Canis latrans) has also been shown to 
be a suitable host for this parasite; in Arctic regions, the ar-
tic fox (Alopex lagopus) is the principal defi nitive host (1). 
Domestic dogs are also highly susceptible defi nitive hosts 
(4); in some areas, such as Alaska (5), People’s Republic of 
China (6), and Europe (7), they can play an additional or 
even the dominant role as an infection source for humans.
The documented area of E. multilocularis endemicity 
in Europe has recently increased (3,7,8). However, whether 
this increase results from a true extension of the geographic 
range or simply increased detection in populations of 
wildlife not previously investigated is still unclear (1). 
Similarly, new distribution ranges have been reported in 
North America. In addition to being found in the tundra 
zone of Alaska and Canada, the parasite has now been 
recorded in 3 Canadian provinces and an additional 11 
contiguous US states (9).
Important changes have occurred in the population 
dynamics of foxes in central Europe. Between 1970 and the 
mid-1980s, fox populations decreased during an epidemic 
of rabies. After the successful establishment of anti-rabies 
vaccination programs, fox populations increased almost 
4-fold (10). At the same time, fox habitat extended into 
urban areas and is still progressing. For example, large 
fox populations have now become established in all major 
cities and towns in Switzerland. In the largest city, Zurich, 
the number of foxes shot or found dead within the city 
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boundaries increased 20-fold since 1985 (10). The reasons 
for the increase in the fox populations have been attributed 
to ecologic factors, the successful vaccination campaign 
against fox rabies, and the increase in anthropogenic food 
supplies (7,10).
In the core European area for AE, which includes 
Switzerland as well as neighboring France and Germany, 
high prevalence rates (35%–65%) of E. multilocularis in 
foxes have been consistently recorded (3,7,8,11). However, 
several studies have shown that the prevalence rates have 
been increasing in certain regions. For example, recent 
parasite density estimates in southwestern Germany 
were 10× higher than estimates before 1990 (3,8), and 
unexpectedly high prevalence rates in several urban fox 
populations have been reported (7). The combination of 
increased fox populations and increased parasite prevalence 
within these populations has led to a considerable increase 
in the overall parasite biomass per surface unit.
A question of major public health importance in 
central Europe is whether the growing fox populations that 
have high prevalence of infection and the colonization of 
densely populated urban areas by foxes could increase risk 
for transmission of AE to humans and lead to an increase 
of clinical cases. Until 2000, no statistically signifi cant 
increase in AE had been recorded in Switzerland (1). We 
report countrywide annual incidence rates of human AE in 
Switzerland in recent years (1993–2005) and compare them 
with incidence data for previous years (1956–1992). The 
European Echinococcosis Registry (11) gives summary 
data for 559 cases of AE from central Europe between 
1988 and 2000, which includes data from 112 of the Swiss 
cases in the present report. The incidence data were related 
to the fox population dynamics. Because Switzerland has 
been consistently collecting comprehensive data on AE 
in humans for 50 years, conditions for such long-term 
assessments are favorable.
Methods
We retrieved retrospective data of extensive AE case-
fi nding studies covering all of Switzerland for 1956–1992 
(Table). We included additional data from the Swiss 
National Center for Echinococcosis, collected when 
echinococcosis was a reportable disease (1987–1996), 
and data for 1996–2005, collected from databases of the 
University Hospitals of Zurich, Berne, and Lausanne, the 3 
major centers for AE treatment in Switzerland.
Furthermore, we analyzed serodiagnostic data 
compiled from the 3 main diagnostic laboratories for 
parasitic diseases in Switzerland that offer reliable (and 
methodically comparable) immunodiagnosis of human 
AE (Institutes of Parasitology, Universities of Zurich and 
Bern, Swiss Tropical Institute in Basel). Cases that were 
diagnosed primarily on the basis of serologic testing results 
were further assessed by sending questionnaires to involved 
family doctors or by conducting retrospective analysis of 
the patients’ history obtained from the treating hospitals.
Inclusion criteria were as applied previously (11). 
These were 1) diagnosis of AE by positive, species-specifi c 
serologic testing (15), 2) AE-characteristic imaging fi ndings, 
and 3) if available, AE-characteristic histopathologic 
fi ndings and species-specifi c molecular analysis by PCR. 
Seropositive persons who lacked characteristic imaging 
features or histologic or molecular diagnosis were excluded 
from the study. All data were entered by using only personal 
initials, birth date, and sex; patients remained anonymous. 
Data were collected in a single database (Microsoft Excel; 
Microsoft Corp., Redmond, WA, USA) to prevent multiple 
counting of patients.
For cases that occurred during 1993–2005, for which 
data on the clinical records were available, we used the 
PNM (primary, neighboring, metastasis) staging system, 
specifi cally, location and extension of the primary lesion, 
involvement of neighboring organs, and presence or 
absence of metastasis (16). We determined the stage of 
disease (stages I–IV) by using this PNM system. Stages I 
and II are more likely to represent subclinical disease and 
are often diagnosed by chance. Such cases, if detected 
early, are more amenable to curative resection. Patients 
with PNM stage III or IV are more likely to have advanced 
clinical disease. They have more limited treatment options, 
such as individualized interventional measures and lifelong 
chemotherapy (17). The stage of cases diagnosed during 
Table. Data from reported case-finding studies on human alveolar echinococcosis, 1956–2005, Switzerland 
Sex, no. (%) 
Study (reference no.) Years No. cases 
Mean annual 
incidence/100,000
population
Mean age
±SD, y Male Female
Drolshammer (12) 1956–1969 122 0.15 54.2 ± 18.2 65 (53)* 57 (47) 
Gloor (13) 1970–1983 145 0.16 55.0 ± 16.0 79 (54)* 66 (46) 
Eckert (14) 1984–1992 71† 0.12 52.0 ± 17.7 33 (46) 38 (54) 
This study  1993–2000 60 0.10 52.5 ± 18.4 26 (43) 34 (57) 
This study  2001–2005 96 0.26‡ 54.5 ± 17.3 42 (44) 54 (56) 
Total 1956–2005 494 0.15 54.0 ± 17.3 245 (49.7) 248 (50.3) 
*Proportion of cases in male patients was significantly higher during 1956–1983 than 1984–2005 (p<0.05). 
†Six more cases from 1984–1992 have been included in this study. 
‡Significantly increased compared with1984–2000 (p for trend <0.01). 
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1993–2000 was compared with stage of cases diagnosed 
during 2001–2005 by converting the stage to a score. For 
example, patients with stage I disease were scored as 1 
and those with stage IIIb disease were scored as 3.5. To 
determine whether earlier or later diagnosis during different 
periods might partly account for any trend in the change of 
incidence, the mean score of cases diagnosed during 1993–
2000 was compared with mean score of those diagnosed 
during 2001–2005. PNM scores were available for 50% 
(51 cases) of the 2001–2005 cases and for 40 (68%) of the 
1993–2000 cases. For 2001–2005, the average age of case-
patients with available PNM scores was 54 years (SD 17 
years). This average did not signifi cantly differ from the 
average of 50 years (SD 18 years) of case-patients with PNM 
scores for 1993–2000 (p = 0.19, Student t test). Likewise, 
the proportion of male patients with scores for 2001–2005 
(37%) did not signifi cantly differ from the proportion of 
male patients with scores for 1993–2000 (44%) (p = 0.35, 
Fisher exact test). Therefore, we found no evidence of bias 
due to incomplete data.
We retrieved data regarding fox population sizes from 
the Swiss federal hunting statistics (www.wild.unizh.ch/
jagdst). These data, based on annual hunting numbers, indi-
cate trends over a long period of time (18). Human popula-
tion data for Switzerland originated from the Swiss Federal 
Statistical Offi ce (www.bfs.admin.ch).
To perform our statistical calculations, we used 
Microsoft Excel. Differences in human incidence rates and 
differences in numbers of reported foxes were analyzed by 
χ2 test for trend. Proportions of male and female patients and 
the proportion of patients who had radical liver resection 
were analyzed by χ2 test. Data for PNM scores were tested 
for normality and compared by using the Student t test. To 
smooth out annual fl uctuations and better visualize longer 
term trends, we present data for number of foxes and 
incidence of human AE cases as 5-year moving averages. 
Results
A total of 494 cases of human AE were diagnosed 
in Switzerland during 1956–2005. The mean age at time 
of diagnosis (54 years, range 12–89) did not change 
signifi cantly over time (Table). The numbers of male and 
female patients were similar, although the trend was toward 
a decreasing proportion of male patients over the observation 
period. Male patients accounted for 53%–54% of patients 
during 1956–1983 compared with 43%–46% during 1984–
2005 (p<0.05) (Table). The incidence of human AE during 
the observation period is shown in the Figure. The highest 
annual incidence per 100,000 was recorded in 2003 (0.38; 
28 new cases); the lowest, in 1996 (0.04; 3 new cases). The 
mean annual incidence per 100,000 was 0.10 during 1993–
2000 and increased to 0.26 during 2001–2005 (p<0.01) 
(Figure, Table). The estimated fox population increased 
≈4-fold during 1984–1993 (Figure) (p<0.001).
The mean PNM score for cases diagnosed during 
1993–2000 was 2.41 (SD 1.3), which was not signifi cantly 
different from the mean PNM score of 2.44 (SD1.2) for 
cases diagnosed during 2001–2005. The proportion of 
patients who had a radical liver resection was highest 
during 1996–2000 (75.3%) and lowest during 1991–1995 
(37.5%) and 2001–2005 (54.9%) (p<0.001).
Discussion
The incidence of human AE in Switzerland has  exhibited 
2 trends during the past 50 years. After a slow but steady 
decline during 1956–1999, incidence has signifi cantly 
increased since the year 2000 (Figure). A reasonable 
explanation for this fi nding may be the urbanization of the 
E. multilocularis cycle, which has resulted in an increase 
in the number and proportion of infected urban foxes in 
areas with high human populations, thereby increasing the 
infection risk for the human population (7). The increase 
of the fox population density started in ≈1985, some 
10–15 years before the increased numbers of human AE 
cases (Figure). This temporal delay is consistent with the 
suggested latent or asymptomatic period of 5–15 years 
before development of clinically apparent AE in humans 
(19). Improved diagnostic accuracy, due to modern imaging 
technologies such as computerized tomography (20), is 
unlikely to account for this increase. Such improvements 
in diagnostic accuracy would be expected to lead to earlier 
Figure. Actual data points with moving 5-year average for annual 
incidence of human alveolar echinococcosis in Switzerland (A) and 
annual number of foxes hunted per year in Switzerland (B), used as 
a fox population density marker. 
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detection with a shift to PNM stages I and II at the time 
of diagnosis, but such a trend has not been recorded. In 
addition, earlier, more local investigations have already 
indicated an increase in AE seropositivity in defi ned human 
populations at risk in central Europe (21,22) without a 
concomitant increase in clinical AE cases. An increase in 
the rate of AE seropositivity that precedes that of clinical 
AE is therefore consistent with increased exposure and a 
temporally delayed rise in the number of clinical cases.
The use of foxes recorded in hunting statistics or 
hunting indices as a measure of the fox population is 
susceptible to bias and should be used only to describe 
trends from large areas (>1,000 km2) over long periods 
(>5 years) (18). For this reason, the temporal trends in the 
size of the fox population were estimated by using hunting 
returns compiled for 50 years for the entire territory of 
Switzerland (42,000 km2). Therefore, we can conclude 
that the incidence of human AE appears to be increasing 
in Switzerland and that this increase was preceded 10 years 
earlier by a parallel increase and urbanization of the fox 
population.
The potential extent of this emerging epidemic of 
human AE cannot be predicted. Future trends will depend 
on the intensity of present and future contamination of the 
environment with E. multilocularis eggs as well as on the 
number of susceptible persons exposed to the parasite. In 
this respect, the human AE epidemic appears analogous to 
that of human variant Creutzfeldt-Jakob disease, for which 
predictions of future disease trends have been hampered by 
uncertain knowledge of incubation periods and unknown 
relationships between the risk for disease and host factors 
(23,24). Nevertheless, the temporal proliferation of E. 
multilocularis biomass in the main defi nitive host has 
increased the infection pressure for a large part of the human 
population in Switzerland. Likewise, other susceptible 
canid species involved in the life cycle of the parasite could 
present additional threats, in Europe and elsewhere. Within 
the past decade, for example, coyotes in the United States 
have become established in suburban areas with moderate 
to dense human populations (25). Because this species is 
a suitable defi nitive host of E. multilocularis (9), risk for 
transmission to humans in the United States and Canada 
may increase markedly.
In conclusion, public health authorities in 
echinococcosis-endemic areas should establish coordinated 
systems of continuous surveillance and risk assessment, 
combined with measures to reduce illness and death from 
AE in human populations (1). Furthermore, new control 
strategies, including strategic deworming of foxes and other 
wild canids by using anthelminthic baiting options, should 
be further evaluated and developed. Such strategies should 
preferably target suburban areas that have high human and 
wild canid population densities (7).
Dr Schweiger is a research assistant at the Institute of Parasi-
tology of the University of Zurich. His research interests include 
epidemiology of human AE in Switzerland.
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